Background: The recent implementation of PET with prostate specific membrane antigen (PSMA)-specific radiotracers into the clinical practice has resulted in the significant improvement of accuracy in the detection of prostate carcinoma (PCa). PSMA-expression in ganglia has been regarded as an important pitfall in prostate carcinoma-PET diagnostics but has not found any practical use for diagnosis or therapy.
Background
Prostate-specific membrane antigen (PSMA) is a membrane bound type II zinc metallopeptidase which hydrolyzes C-terminal glutamate residues of small peptides in the extracellular space. The natural substrates of PSMA are the neurotransmitter N-acetylaspartylglutamate (NAAG) [1] and polyglutamate folate (pteroylpolyglutamate) [2] . PSMA expression is strongly upregulated in prostate carcinoma (PCa) and correlates with tumor malignancy (reviewed in [3] ) making PSMA an attractive target for PCa diagnosis and treatment. In tumors, PSMA is supposed to be involved in folate uptake [4] as well as in laminin proteolysis which favor angiogenesis and re-endothelialization [5, 6] . The released glutamate binds to tumor cell metabotropic glutamate receptors stimulating tumor growth via phosphoinositide 3-kinaserelated signaling pathways [7] . In recent years, PET or SPECT tracers for PSMA imaging have become important tools for PCa diagnostics [8] [9] [10] . In addition, radioligands labeled with therapeutic radionuclides like 177 Lu and 225 Ac have been successfully used for PSMAtargeted radiotherapy in prostate cancer [11, 12] . A suitable probe for molecular imaging or targeted radiotherapy should combine high specificity and long retention in target tissue with a rapid washout from non-target organs [13] . Usually, preclinical validation of novel radioligands for tumor imaging comprises in vitro studies of tracer uptake in target positive and negative cell lines as well as in vivo evaluation in appropriate animal models. The most common approaches employ tumor xenografts in immunodeficient animals [14] . While these models are generally well suited for assessment of target specificity and tumor binding kinetics, there are also some drawbacks. Since the blood vessels and stroma cells in human tumor xenografts are of murine origin, their growth is often irregular, and necrotic or cystic areas can be present already in small (8-10 mm) tumors. Poor blood supply can affect the penetration and distribution of imaging agents in tumors. Microbial or viral contamination of tumor cells could significantly affect not only survival and response of the immune deficient murine host but also properties of tumor tissues like immunogenicity, growth rate and metastatic potential [15] . Therefore, immunocompromised animals need to be housed and handled under specific pathogen-free conditions, which is laborious and expensive. For an initial in vivo screening of newly developed PSMA ligands, a facile alternative to xenograft models may be beneficial.
PSMA-specific uptake of PET tracers in human cervical, coeliac and sacral ganglia is well documented in the literature [16] [17] [18] . Similar to humans, rat ganglionic PSMA is expressed by satellite glial cells [19] , which envelop the neuronal cell bodies of peripheral ganglia. Electron microscopic studies have shown that PSMA is mainly localized in the cell membrane of satellite cells [20] . PSMA/β-actin expression ratio is 1.5 for rat dorsal root ganglia [19] , while it amounts to 6.8 for LNCaP prostate carcinoma cells [21] . PSMA in rat dorsal root ganglia shows an enzymatic activity of 9.9 ± 1.7 pmol NAAG/min/mg [20] , while in the superior cervical ganglion PSMA activity (26.5 ± 0.2 pmol NAAG/min/mg) [20] is virtually equal to that of LNCaP cells (29.0 ± 2.6 pmol NAAG/min/mg) [22] , which are broadly used for PCa xenograft models.
Having a size of only 1-2 mm, rat ganglia have the potential to mimic metastases in a very early stage. Rat PSMA comprises 752 amino acids (vs. 750 in humans), and is about 91% homologous to human PSMA. Importantly, all amino acid residues of the active site are essentially the same as those in the human homologue. The only exception is Ser 548 in the rat instead of Gly 548 in the human protein [23] . Not surprisingly, rat and human PSMA show comparable kinetic parameters for hydrolysis of NAAG and similar inhibition profiles [23] .
We have already used peripheral ganglia of healthy rats for the preclinical screening of novel PSMA ligands [24] . This study resulted in discovery of a PSMA PET probe with favorable imaging properties which is already used in clinic [25, 26] 18 F]FPy-TFP (1-10 GBq) in EtOH (500 mL) was added and the mixture was allowed to stir at 45°C for 3-5 min. The mixture was quenched with H 2 O (2 mL) and purified by preparative HPLC (eluent: saline (0.9% NaCl) with 10% EtOH); flow rate: 8 mL/min, column: Synergi 4 μm Hydro-RP 80 Å 100 × 21.2 mm; retention time: 7.0 min). Finally, the purified product was passed through a sterile 0.2 μm filter. 18 F]fluoride was eluted with 0.5 M NaOAc (pH 4.5; 0.5 mL). An aliquot of the resulting solution (200 μL) was added to a mixture of 6 μL 0.01 M AlCl 3 in 0.05 M NaOAc (pH 4 and 50 μg Glu-NH-CO-NH-Lys(Ahx-HBED-CC) (PSMA-11) in 200 μL EtOH. The reaction mixture was allowed to stir at 100°C for 5 min. After cooling to room temperature the crude product was passed through a HLB column, which was washed with NaOAc buffer (10 mL, pH = 4.3). The labeled product was eluted using 1:1 saline/EtOH (2 mL 6 in 150 μL matrigel) was injected subcutaneously in to the scruff of the neck between the shoulders of the mice. After 3 weeks, the mice developed subcutaneous tumors with volumes of about 1 cm 3 . The health status of all animals was monitored daily and was stable throughout the experiments. After completion of the measurements, the tumor-bearing mice were sacrificed by cervical dislocation. Apart from the one rat used for autoradiography, the rats were not sacrificed and remained in our animal facility.
PET
A small animal PET/SPECT/CT scanner (Triumph II, Trifoil, USA) and a stand-alone small animal PET scanner (Focus 220, Siemens) were used. The tracer was injected during a short anesthesia (2% isoflurane in 30% oxygen/70% air) into the lateral tail vein ([ 18 F]DCFPyL: 14-71 MBq, n = 6); [Al 18 F]PSMA-11: 25-54 MBq, n = 3; [ 68 Ga]PSMA-11: 13-51 MBq, n = 3). Additionally, in three rats, [ 18 F]DCFPyL was injected together with the PSMA inhibitor, 2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA; 23 mg/kg).
Imaging started 60 min after tracer injection and ended 120 min after injection. Animals were fixed in an animal holder with anesthesia mask (2% isoflurane in 30% oxygen/70% air). Breathing rate and body temperature were monitored and held at approx. 60 breaths/min and 37°C, respectively. Focus 220 emission scans were followed by an 8 min transmission scan with a rotating 57 Co-point source, Triumph II emission scans by a 10 min CT scan (70 kV, 500 μA). The rats were sacrificed at the following day, and dorsal root ganglia were removed and fixed overnight in 4% paraformaldehyde in PBS (pH 7.4) for immunohistochemistry.
For mouse scans (n = 5), the Triumph II PET/SPECT/ CT scanner was used, and 21- 
Immunohistochemistry
Consecutive formalin-fixed, paraffin-embedded longitudinal tissue sections (2 μm thick) of dorsal root ganglia were dewaxed in xylene and rehydrated through graded concentrations of ethanol to distilled water. Sections were then immersed in 10 mm sodium citrate buffer (pH 6.0) and processed for antigen retrieval in the microwave oven at 600 W for 5 min. For blocking of endogenous peroxidase activity, the sections were treated with 0.3% H 2 O 2 solution for 15 min at ambient overnight at 4°C. Subsequently, the sections were washed tree times with TBST and exposed for 60 min to peroxidase-linked anti-mouse immunoglobulin antibody (1:500 diluted in TBST, Cell Signaling Technology Europe B.V., Frankfurt-Main, Germany). Color development was performed using diaminobenzidine and sections were counterstained with haematoxylin/eosin.
Statistical analysis
All statistical analyses were performed with Prism 6.0f for Mac OS X. Biodistribution of tracers was compared using One-way ANOVA followed by Dunnett's multiple comparison test. Correlation between tumor tracer uptake and tumor size was assessed with the Pearson correlation test. Variances of tracer uptake in mouse tumor xenografts and rat SCG were compared with an F-Test for unequal variance.
Results

Biodistribution of PSMA specific tracers in healthy rats
In healthy rats, [ 18 F]DCFPyL accumulated in peripheral ganglia with the highest uptake in the ganglion of the trigeminal nerve (37.9 ± 9.9 SUV BW , measured 60-120 min after injection; n = 6; Fig. 1 ). The eight focal accumulations of radioactivity detected in the cervical intervertebral foramina were assigned to the dorsal root ganglia (Figs. 2a-e, 3a, 4) . Autoradiography confirmed that dorsal root ganglia, but not the spinal cord or the spinal nerves, accumulated [ 18 F]DCFPyL (Fig. 2f-h ). Radioactivity accumulation was also visible in the stellate ganglion, salivary glands and heart (Fig. 3a) . The uptake of [ 18 F]DCFPyL in the SCG was 20.2 ± 5.8 SUV BW and the signal-to-noise ratio was 6.7 ± 2.6. Co-application with 2-PMPA strongly decreased radioactivity accumulation in the SCG ( Fig. 3b; Table 1 ).
[Al 18 F]PSMA-11 suffered from substantial in vivo defluorination (Fig. 3c) reflected by high radioactivity PET images obtained with [ 68 Ga]PSMA-11 were more blurry with the overall background higher compared to that observed with the 18 F-labeled tracers (Fig. 3d) (Fig. 3f ) . When measured twice in the same animal, even with two different PSMA tracers, the individual shape of the SCG and dorsal root ganglia chain was clearly identifyable (Fig. 3g) .
Immunohistochemistry
Immunohistochemistry of dorsal root ganglia with a PSMA-specific antibody revealed that immunoreactivity was confined to the satellite glial cells, but absent in neurons (Fig. 4d) . This finding confirms that the accumulation of radioactivity observed in the peripheral (Fig. 4b ) reflects PSMA expression in the ganglionic satellite cells.
Comparison with LNCaP xenografted mice
In LNCaP xenografted mice, peripheral ganglia were also discernible, but were too small to provide delineated structures. Although LNCaP cells were inoculated on the same day, tumor sizes varied considerably (36-444 mm 3 ). Tumor xenografts showed a heterogeneous uptake of [ 18 F]DCFPyL (Fig. 5a) . Therefore, we used the voxel with highest activity SUV BWmax rather than the mean value of the whole tumor VOI. [ 
Discussion
Our results demonstrate that PSMA-targeted probes significantly accumulate in the rat peripheral ganglia due to specific binding to PSMA expressing satellite cells. Therefore, this structure might be used as a reference organ in the evaluation of PSMA ligands. The rat superior cervical ganglia are easy-to-recognize tissues which fit in the axial field of view of typical μPET scanners together with the cervical dorsal root ganglia, heart and the frontal part of the liver. They are located far from any bone structures. Therefore, the sufficient spatial separation should exclude the possibility of significant "spillover" effects and allow quantification even in the case of tracer defluorination resulting in high accumulation of radioactivity in bone. Consequently, we choose SCG as a reference tissue for the exemplary comparative evaluation of PSMA ligands.
Our study showed significant differences between the tracers with regard to their image parameters. 68 Ga compared to that of 18 F, as well as to scattered photons originating from high energy emission photons of 68 Ga [35] , but also higher background activity. Superior image quality of [ 18 F]DCFPyL due to low beta energy of 18 F was already described in patients [8, 36] . This effect was even more pronounced in small animals.
[ [38] , and can presumably be attributed to poor vascularization [15] and, consequently, low blood supply of small tumor xenografts. Therefore, PSMA tracers should be evaluated in animals bearing xenografts of similar volumes to avoid inconsistent uptake data (Fig. 4c) . Our results have shown that tumors require a size of 58 mm 3 to match the [ 18 F]DCFPyL uptake of the SCG. Although peripheral ganglia are small (< 10 mm 3 ), they are rather densely vascularized [39] , similar to metastases > 1 mm 3 [40] . Therefore inter-individual variance of tracer accumulation in ganglia was low. The variance can be further reduced by application of the same healthy rats for the evaluation of several PSMA tracers. This is infeasible in tumor xenograft-bearing animals owing to the continuous tumor growth and tumor size-associated structural and metabolic tissue changes.
Conclusions
While PSMA-expression in ganglia had been regarded as an important pitfall in prostate carcinoma-PET diagnostics [17] and had not found any practical use, we explored this phenomenon for the evaluation of PCa imaging agents in healthy rats.
We demonstrated the applicability of the peripheral ganglia of healthy rats as a non-invasive and inexpensive 18 F]DCFPyL in rat SCG and mouse tumor xenografts. There was no significant difference between the two models. Abbreviations: B: bladder; K: kidney; SCG: superior cervical ganglion. Scale bar: 1 cm native model of small PCa lesions. Furthermore, our study revealed the non-inferiority of the novel model compared to conventionally used tumor xenografts in immune compromised rodents with regard to reproducibility and stability of the PSMA signal. The SCGs were always accessible for quantification of tracer uptake independently from tracer defluorination. The cervical dorsal root ganglia were also easily identifiable provided the radioligand was metabolically stable and defluorination did not occur. In contrast to the tumor xenograft model, where PSMA-specific uptake correlated linearly with tumor size, inter-and intra-individual variance of tracer accumulation in ganglia was low. Importantly, tumor burden-associated pain and adverse effects were avoided entirely. To the best of our knowledge, this is the first tumor-free model suitable for the in vivo evaluation of tumor imaging agents. 
